This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
rsi: Archive
MarketAxess (MKTX) Loses -9.63% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
MarketAxess (MKTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
MKTXPositive Net Change
rsi stock-price-movement
After Plunging -15.12% in 4 Weeks, Here's Why the Trend Might Reverse for Gevo (GEVO)
by Zacks Equity Research
Gevo (GEVO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
GEVONegative Net Change
rsi stock-price-movement
Here's Why Phunware (PHUN) is Poised for a Turnaround After Losing -36.04% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Phunware (PHUN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
PHUNNegative Net Change
rsi stock-price-movement
Nouveau Monde Graphite (NMG) Loses -12.06% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Nouveau Monde Graphite (NMG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
NMGNegative Net Change
rsi stock-price-movement
Down -15.63% in 4 Weeks, Here's Why You Should You Buy the Dip in ACM Research (ACMR)
by Zacks Equity Research
ACM Research (ACMR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
ACMRNegative Net Change
rsi stock-price-movement
Here's Why Vista Outdoor (GEAR) is Poised for a Turnaround After Losing -56.92% in 4 Weeks
by Zacks Equity Research
Vista Outdoor (GEAR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
GEARNegative Net Change
rsi stock-price-movement
GDEV Inc. (GDEV) Loses -15.68% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
GDEV Inc. (GDEV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
GDEVNegative Net Change
rsi stock-price-movement
After Plunging -38.05% in 4 Weeks, Here's Why the Trend Might Reverse for Select Medical (SEM)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Select Medical (SEM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
SEMNegative Net Change
rsi stock-price-movement
After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD)
by Zacks Equity Research
Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
PRLDNegative Net Change
rsi stock-price-movement
Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)
by Zacks Equity Research
Cassava Sciences (SAVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
SAVANegative Net Change
rsi stock-price-movement
Down -16.15% in 4 Weeks, Here's Why Maximus (MMS) Looks Ripe for a Turnaround
by Zacks Equity Research
Maximus (MMS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
MMSNegative Net Change
rsi stock-price-movement
Boundless Bio, Inc. (BOLD) Loses -19.52% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Boundless Bio, Inc. (BOLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
BOLDNegative Net Change
rsi stock-price-movement
ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
ALX Oncology Holdings (ALXO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ALXONegative Net Change
rsi stock-price-movement
Down -8.09% in 4 Weeks, Here's Why Steven Madden (SHOO) Looks Ripe for a Turnaround
by Zacks Equity Research
Steven Madden (SHOO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
SHOOPositive Net Change
rsi stock-price-movement
Down -12.82% in 4 Weeks, Here's Why Uber (UBER) Looks Ripe for a Turnaround
by Zacks Equity Research
Uber (UBER) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
UBERPositive Net Change
rsi stock-price-movement
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX)
by Zacks Equity Research
Compass Therapeutics, Inc. (CMPX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CMPXNegative Net Change
rsi stock-price-movement
Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Lineage Cell (LCTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
LCTXNegative Net Change
rsi stock-price-movement
Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
RLAYNegative Net Change
rsi stock-price-movement
Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Biodesix (BDSX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
BDSXNegative Net Change
rsi stock-price-movement
Here's Why WW International (WW) is Poised for a Turnaround After Losing -26.67% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for WW International (WW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
WWPositive Net Change
rsi stock-price-movement
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for PDS Biotechnology (PDSB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
PDSBNegative Net Change
rsi stock-price-movement
Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Agenus (AGEN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
AGENNo Net Change
rsi stock-price-movement
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround
by Zacks Equity Research
CytomX Therapeutics (CTMX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
CTMXNegative Net Change
rsi stock-price-movement
Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
RLAYNegative Net Change
rsi stock-price-movement
After Plunging -13.91% in 4 Weeks, Here's Why the Trend Might Reverse for Booz Allen (BAH)
by Zacks Equity Research
Booz Allen (BAH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
BAHPositive Net Change
rsi stock-price-movement